$ESPR
Esperion Therapeutics Inc

2019 Q3 Form 10-Q Financial Statement

#000110465919060531 Filed on November 06, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q3 2018 Q2
Revenue $981.0K $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $18.47M $9.000M $7.000M
YoY Change 105.2% 57.89% 29.63%
% of Gross Profit
Research & Development $48.28M $41.55M $39.52M
YoY Change 16.2% 3.62% 3.47%
% of Gross Profit
Depreciation & Amortization $90.00K $70.00K $60.00K
YoY Change 28.57% 0.0% 0.0%
% of Gross Profit
Operating Expenses $66.75M $50.56M $46.48M
YoY Change 32.01% 10.64% 6.36%
Operating Profit -$65.77M -$50.56M -$46.48M
YoY Change 30.07%
Interest Expense $3.996M $600.0K $700.0K
YoY Change 566.0% -800.0%
% of Operating Profit
Other Income/Expense, Net $1.387M $651.0K $750.0K
YoY Change 113.06% 8.5% 87.5%
Pretax Income -$68.40M -$49.90M -$45.70M
YoY Change 37.07% 10.4% 5.54%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$68.38M -$49.91M -$45.73M
YoY Change 37.0% 10.42% 5.61%
Net Earnings / Revenue -6970.13%
Basic Earnings Per Share -$2.52 -$1.71
Diluted Earnings Per Share -$2.52 -$1.862M -$1.71
COMMON SHARES
Basic Shares Outstanding 27.17M shares 26.79M
Diluted Shares Outstanding 27.17M shares 26.79M

Balance Sheet

Concept 2019 Q3 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $243.9M $159.2M $180.2M
YoY Change 53.18% -21.73% 7.65%
Cash & Equivalents $212.0M $26.76M $24.38M
Short-Term Investments $31.88M $132.5M $155.8M
Other Short-Term Assets $9.600M $9.000M $8.700M
YoY Change 6.67% 157.14% 148.57%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $253.5M $168.2M $188.9M
YoY Change 50.69% -18.67% 10.53%
LONG-TERM ASSETS
Property, Plant & Equipment $958.0K $600.0K $300.0K
YoY Change 59.67% 20.0% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $5.200M $21.60M
YoY Change -100.0% -95.08% 57.66%
Other Assets
YoY Change
Total Long-Term Assets $1.810M $5.800M $22.00M
YoY Change -68.79% -94.54% 53.85%
TOTAL ASSETS
Total Short-Term Assets $253.5M $168.2M $188.9M
Total Long-Term Assets $1.810M $5.800M $22.00M
Total Assets $255.3M $174.0M $210.9M
YoY Change 46.71% -44.43% 13.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $23.74M $18.60M $22.50M
YoY Change 27.61% -4.62% 20.32%
Accrued Expenses $31.20M $23.70M $12.30M
YoY Change 31.65% 69.29% 17.14%
Deferred Revenue $2.618M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $200.0K
YoY Change -88.89%
Total Short-Term Liabilities $57.52M $42.30M $35.00M
YoY Change 35.98% 20.86% 12.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $129.2M
YoY Change
Total Long-Term Liabilities $129.2M $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $57.52M $42.30M $35.00M
Total Long-Term Liabilities $129.2M $0.00 $0.00
Total Liabilities $186.8M $42.30M $35.00M
YoY Change 341.51% 20.86% 12.54%
SHAREHOLDERS EQUITY
Retained Earnings -$633.3M
YoY Change
Common Stock $27.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.51M $131.7M $175.9M
YoY Change
Total Liabilities & Shareholders Equity $255.3M $174.0M $210.9M
YoY Change 46.71% -44.43% 13.88%

Cashflow Statement

Concept 2019 Q3 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$68.38M -$49.91M -$45.73M
YoY Change 37.0% 10.42% 5.61%
Depreciation, Depletion And Amortization $90.00K $70.00K $60.00K
YoY Change 28.57% 0.0% 0.0%
Cash From Operating Activities -$58.03M -$37.53M -$39.20M
YoY Change 54.62% 4.57% 49.5%
INVESTING ACTIVITIES
Capital Expenditures -$360.0K -$50.00K $0.00
YoY Change 620.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$4.960M $40.08M $31.57M
YoY Change -112.38% -131.43% 16.45%
Cash From Investing Activities -$5.310M $40.03M $31.57M
YoY Change -113.27% -131.39% 16.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 970.0K -130.0K 1.190M
YoY Change -846.15% -100.08% -421.62%
NET CHANGE
Cash From Operating Activities -58.03M -37.53M -39.20M
Cash From Investing Activities -5.310M 40.03M 31.57M
Cash From Financing Activities 970.0K -130.0K 1.190M
Net Change In Cash -62.37M 2.370M -6.440M
YoY Change -2731.65% 264.62% -1362.75%
FREE CASH FLOW
Cash From Operating Activities -$58.03M -$37.53M -$39.20M
Capital Expenditures -$360.0K -$50.00K $0.00
Free Cash Flow -$57.67M -$37.48M -$39.20M
YoY Change 53.87% 4.43% 49.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26824859
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
espr:CollaborationRevenueMember
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
espr:CollaborationRevenueMember
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27178230
espr Fair Value Measurement Liability Transfers Between Levels
FairValueMeasurementLiabilityTransfersBetweenLevels
0
CY2018Q3 espr Fair Value Measurement Liability Transfers Between Levels
FairValueMeasurementLiabilityTransfersBetweenLevels
0
espr Fair Value Measurement Liability Transfers Between Levels
FairValueMeasurementLiabilityTransfersBetweenLevels
0
CY2019Q3 espr Fair Value Measurement Liability Transfers Between Levels
FairValueMeasurementLiabilityTransfersBetweenLevels
0
dei Entity Central Index Key
EntityCentralIndexKey
0001434868
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35986
dei Entity Registrant Name
EntityRegistrantName
Esperion Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1870780
dei Entity Address Address Line1
EntityAddressAddressLine1
3891 Ranchero Drive, Suite 150
dei Entity Address City Or Town
EntityAddressCityOrTown
Ann Arbor
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48108
dei City Area Code
CityAreaCode
734
dei Local Phone Number
LocalPhoneNumber
887-3903
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ESPR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27327409
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
211978000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
958000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36973000
CY2019Q3 us-gaap Restricted Cash
RestrictedCash
928000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
31883000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
99050000
CY2019Q3 espr Prepaid Clinical Development Costs Current
PrepaidClinicalDevelopmentCostsCurrent
5653000
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
520000
CY2018Q4 espr Prepaid Clinical Development Costs Current
PrepaidClinicalDevelopmentCostsCurrent
5275000
CY2019Q3 espr Operating Lease Right Of Use Asset Current
OperatingLeaseRightOfUseAssetCurrent
260000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2758000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1334000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
253460000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
142632000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
64333000
CY2019Q3 espr Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
128420000
CY2019Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
56000
CY2018Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
56000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
243000
CY2019Q3 espr Operating Lease Right Of Use Asset Non Current
OperatingLeaseRightOfUseAssetNonCurrent
796000
CY2019Q3 us-gaap Assets
Assets
255270000
CY2018Q4 us-gaap Assets
Assets
143451000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
23735000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
44893000
CY2019Q3 espr Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
20954000
CY2018Q4 espr Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
16039000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9944000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3401000
CY2019Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2618000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
267000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
57518000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
820000
CY2019Q3 us-gaap Liabilities
Liabilities
186758000
CY2018Q4 us-gaap Liabilities
Liabilities
64333000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27178230
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26824859
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
27000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
701794000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
677511000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-319000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-633320000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-598101000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
68512000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
79118000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
255270000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
143451000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
981000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147382000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
981000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147382000
CY2019Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
48281000
CY2018Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
41551000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
137377000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
122015000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18468000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9011000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44142000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21921000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
66749000
us-gaap Operating Income Loss
OperatingIncomeLoss
-143936000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
50562000
us-gaap Operating Expenses
OperatingExpenses
181519000
us-gaap Operating Expenses
OperatingExpenses
143936000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-65768000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-50562000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2193000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34137000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
214140000
CY2019Q3 us-gaap Interest Expense
InterestExpense
3996000
us-gaap Interest Expense
InterestExpense
3996000
us-gaap Interest Expense
InterestExpense
28000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1387000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
651000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2914000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-68377000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-49911000
us-gaap Net Income Loss
NetIncomeLoss
-35219000
us-gaap Net Income Loss
NetIncomeLoss
-141771000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.52
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.86
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.30
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27171769
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26804026
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26995661
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26732733
CY2019Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
27000
CY2018Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
216000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
330000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
285000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68350000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49695000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34889000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-141486000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
79118000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1669000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6636000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
208000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
87379000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
175010000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1887000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6563000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
95000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-54221000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
129334000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1201000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6327000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
27000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-68377000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
68512000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
244691000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9776000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5921000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-118000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-46130000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5495000
us-gaap Depreciation
Depreciation
218000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1597000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5723000
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
187000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-45730000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
175917000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
216000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-49911000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
131745000
us-gaap Profit Loss
ProfitLoss
-35219000
us-gaap Profit Loss
ProfitLoss
-141771000
us-gaap Depreciation
Depreciation
191000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
140000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
134000
espr Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
3996000
us-gaap Share Based Compensation
ShareBasedCompensation
19526000
us-gaap Share Based Compensation
ShareBasedCompensation
17139000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1802000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5267000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2618000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-21158000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1808000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
11614000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
11704000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20347000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-119946000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
26630000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
25481000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
94510000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
127408000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
781000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67099000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
101881000
espr Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs
ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts
124424000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4757000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11401000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1049000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129181000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10352000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
175933000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7713000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36973000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34468000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
212906000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26755000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
74000
CY2019Q3 espr Number Of Patients Enrolled In Global Cardiovascular Outcomes Trial
NumberOfPatientsEnrolledInGlobalCardiovascularOutcomesTrial
14032
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
293000
espr Non Cash Right Of Use Asset
NonCashRightOfUseAsset
31000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to concentrations of credit risk. The Company has established guidelines for investment of its excess cash and believes the guidelines maintain safety and liquidity through diversification of counterparties and maturities.</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1000000.0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147400000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147400000
CY2019Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2600000
CY2019Q3 espr Investments And Cash Amortized Cost
InvestmentsAndCashAmortizedCost
87071000
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11000
CY2019Q3 espr Investments And Cash Fair Value Disclosure
InvestmentsAndCashFairValueDisclosure
87082000
CY2018Q4 espr Investments And Cash Amortized Cost
InvestmentsAndCashAmortizedCost
134138000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
319000
CY2018Q4 espr Investments And Cash Fair Value Disclosure
InvestmentsAndCashFairValueDisclosure
133819000
espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0
CY2018Q3 espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0
espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0
CY2019Q3 espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0
espr Unamortized Transaction Costs On Revenue Interest Agreement
UnamortizedTransactionCostsOnRevenueInterestAgreement
600000
CY2019Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
55600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5303723
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
37.01
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M1D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
83473000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
542875
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
46.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
419628
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
47.06
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
333708
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
14.26
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5093262
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M17D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
45443000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5093262
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
38.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y7M17D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
45443000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3142954
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
33.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M21D
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
39711000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
88000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
338000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
321000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
299000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
217000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1263000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
176000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1087000
CY2019Q3 espr Operating Lease Right Of Use Asset Current
OperatingLeaseRightOfUseAssetCurrent
260000
CY2019Q3 espr Operating Lease Right Of Use Asset Non Current
OperatingLeaseRightOfUseAssetNonCurrent
796000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1056000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
267000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
820000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1087000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5285466
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5349428
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
211978000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26755000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
928000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
212906000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26755000

Files In Submission

Name View Source Status
0001104659-19-060531-index-headers.html Edgar Link pending
0001104659-19-060531-index.html Edgar Link pending
0001104659-19-060531.txt Edgar Link pending
0001104659-19-060531-xbrl.zip Edgar Link pending
espr-20190930.xsd Edgar Link pending
espr-20190930x10q924475.htm Edgar Link pending
espr-20190930x10q924475_htm.xml Edgar Link completed
espr-20190930_cal.xml Edgar Link unprocessable
espr-20190930_def.xml Edgar Link unprocessable
espr-20190930_lab.xml Edgar Link unprocessable
espr-20190930_pre.xml Edgar Link unprocessable
ex-31d1.htm Edgar Link pending
ex-31d2.htm Edgar Link pending
ex-32d1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending